The inhibitors of sodium–glucose cotransporter 2 (SGLT2), officially approved for the treatment of type 2 diabetes (dapagliflozin, licogliflozin, empagliflozin), are also applied in the treatment of patients with heart failure and chronic kidney disease [158,172]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.